Finch Therapeutics Group (FNCH) Short Interest Ratio & Short Volume

Short interest is the volume of Finch Therapeutics Group shares that have been sold short but have not yet been closed out or covered. As of May 15th, investors have sold 19,200 shares of FNCH short. 2.83% of Finch Therapeutics Group's shares are currently sold short. Learn More on Finch Therapeutics Group's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.83% of Finch Therapeutics Group's floating shares are currently sold short.

Finch Therapeutics Group saw a decrease in short interest in May. As of May 15th, there was short interest totaling 19,200 shares, a decrease of 27.3% from the previous total of 26,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Finch Therapeutics Group currently has issued a total of 1,606,000 shares. Some of Finch Therapeutics Group's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Finch Therapeutics Group currently has a public float of 677,300 shares.

2.83% of Finch Therapeutics Group's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Finch Therapeutics Group: Inozyme Pharma, Inc. (10.15%), Sutro Biopharma, Inc. (6.99%), CytomX Therapeutics, Inc. (13.15%), Genenta Science S.p.A. (0.02%), Adaptimmune Therapeutics plc (2.05%), TScan Therapeutics, Inc. (4.21%), Elutia Inc. (0.34%), Corbus Pharmaceuticals Holdings, Inc. (20.28%), ESSA Pharma Inc. (1.68%), Adagene Inc. (0.13%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks.

Short selling FNCH is an investing strategy that aims to generate trading profit from Finch Therapeutics Group as its price is falling. FNCH shares are trading up $0.75 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Finch Therapeutics Group occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of FNCH, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including FNCH, twice per month. The most recent reporting period available is May, 15 2024.